Torrent Pharma recalls around 2.30 lakh bottles of high BP drugs from US
The company is also recalling 18,852 bottles of Losartan Potassium and Hydrochlorothiazide tablets in the strength of 100 mg and 12.5 mg, and 18,780 bottles in the strength of 50 mg and 12.5 mg, it added.
New Delhi: Torrent Pharmaceuticals is recalling 2,29,896 bottles of tablets used for treatment of high blood pressure from the US and Puerto Rico, on account of deviations from the current goods manufacturing norms, the latest Enforcement Report of the US health regulator has said.
Torrent Pharma Inc is recalling 83,016 bottles of Losartan Potassium tablets in the strength of 100 mg, 65,832 bottles in the strength of 50 mg and 43,416 bottles of the drug in the strength of 25 mg, the United States Food and Drug Administration (USFDA) report said.
The company is also recalling 18,852 bottles of Losartan Potassium and Hydrochlorothiazide tablets in the strength of 100 mg and 12.5 mg, and 18,780 bottles in the strength of 50 mg and 12.5 mg, it added.
Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients.
Also Read: No issue of impurities in Losartan in India: Torrent Pharma
The tablets were manufactured by Torrent Pharma in its Mehsana facility in India, the report said.
The reason for the recall is "CGMP Deviations: FDA lab confirmed presence an impurity, N Nitrosodimethylamine (NDEA) contained in the API (active pharmaceutical ingredients) used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million", it added.
The ongoing voluntary recall in the US and Puerto Rico is a class II recall, it added.
According to the USFDA, a class II recall is initiated in a situation, "in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".
Also Read: Torrent Pharma issues voluntary nationwide recall of Losartan Potassium tablets: USFDA
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd